Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | Case report

Infliximab

Various toxicities: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Takeuchi T, et al. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. Drug Safety 46: 991-1005, No. 10, Oct 2023. Available from: URL: https://www.springer.com/journal/40264 Takeuchi T, et al. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. Drug Safety 46: 991-1005, No. 10, Oct 2023. Available from: URL: https://​www.​springer.​com/​journal/​40264
Metadaten
Titel
Infliximab
Various toxicities: 2 case reports
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51519-4

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Fluconazole

Case report

Vancomycin

Case report

Heparin

Case report

Lenvatinib